Psychopharmacology

, Volume 110, Issue 1–2, pp 145–151 | Cite as

Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics

  • John G. Csernansky
  • Catherine T. Wrona
  • Mark E. Bardgett
  • Terrance S. Early
  • John W. Newcomer
Original Investigations

Abstract

The effects of acute (1 day) and subchronic (28 days) treatment with three atypical antipsychotic drugs [clozapine, (±)-sulpiride and (−)-3-PPP] on dopamine and serotonin turnover in both the nucleus accumbens (NA) and corpus striatum (CS) of rodents was compared to haloperidol and saline treatment. The equivalent doses of all drugs were determined based upon their ability to compete in vivo for3H-spiperone binding in the NA and CS. All three atypical drugs, compared to haloperidol, produced preferential elevations of dopamine turnover in the NA. Further, the development of tolerance to this effect was more apparent for the three atypical drugs than for haloperidol. Surprisingly, all three atypical drugs, but not haloperidol, produced changes in serotonin turnover, despite the fact that (±)-sulpiride and (−)-3-PPP have no known direct effects on brain serotonin systems. All three atypical drugs produced acute increases in serotonin turnover in both the NA and CS, followed by later decreases.

Key words

Dopamine Serotonin Neuroleptics Clozapine Sulpiride 3-PPP Haloperidol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnt J (1983) Neuroleptic inhibition of 6,7-ADTN-induced hyperactivity after injection into the nucleus accumbens: specificity and comparison with other models. Eur J Pharmacol 90:47–55Google Scholar
  2. Blaha CD, Lane RF (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decrease dopamine release in striatum and nucleus accumbens in vivo. Neurosci Lett 78:188–204Google Scholar
  3. Carvey PM, Braun AR, Kao L-C, Klawans HL (1987) Effects of dopamine antagonists and apomorphine or regional energy metabolism in rat CNS. Clin Neuropharmacol 10:247–260Google Scholar
  4. Costall B, Naylor RJ (1977) Mesolimbic and extrapyramidal sites for the mediation of stereotyped behaviour patterns and hyperactivity by amphetamine and apomorphine in the rat. Adv Behav Biol 21:47–76Google Scholar
  5. Csernansky JG, Bellows EP, Barnes DE, Lombrozo L (1990) Sensitization to the dopamine turnover-elevating effects haloperidol: the effect of regular- intermittent dosing Psychopharmacology 101:519–524Google Scholar
  6. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121–156Google Scholar
  7. Farde L, Wiesel FA, Nordstrom A-L, Sedvall G (1989) D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31Google Scholar
  8. Goldstein A, Aronow L, Kalman S (1974) Principles of drug action: the basis of pharmacology. Wiley, New York, pp 82–96Google Scholar
  9. Hall H, Ogren SO, Kohler C, Magnusson O (1989) Animal Pharmacology of raclopride, a selective dopamine D2 antagonist. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 123–130Google Scholar
  10. Hjorth S, Carlsson A, Wikstrom H, Lindberg P, Sanchez D, Hacksell U, Arvidsson LE, Svensson U, Nilsson JLG (1981) 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28:1225–1238Google Scholar
  11. Kalen P, Strecker RE, Rosengren E, Bjorklund A (1989) Regulation of striatal serotonin release by the lateral habenula-dorsal raphe pathway in the rat as demonstrated by in vivo microdialysis: role of exciatory amino acids and GABA. Brain Res 492:187–202Google Scholar
  12. Lane RF, Blaha CD (1986) Electrochemistry in vivo: Application to CNS pharmacology. Ann NY Acad Sci 473:50–69Google Scholar
  13. Lappalainen J, Hietala J, Koulu, Syvalahti E (1990) Neurochemical effects of chronic co-administration of ritanserin and haloperidol: comparison with clozapine effects. Eur J Pharmacol 190:403–407Google Scholar
  14. Ljundberg T, Ungerstedt U (1978) Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology 56:239–247Google Scholar
  15. Magnusson O, Fowler CJ, Kohler C, Ogren SO (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25:187–197Google Scholar
  16. McCulloch J, Savaki HE, Sokoloff L (1980) Influence of dopaminergic systems on the lateral habenula nucleus of the rat. Brain Res 194:117–124Google Scholar
  17. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27Google Scholar
  18. Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia. A review. Schizophr Bull 2:19–76Google Scholar
  19. Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246Google Scholar
  20. Neimeggers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24:2201–2216Google Scholar
  21. Ogren SO, Hall H, Kohler C, Magnusson O, Sjostrand SE (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine mediated motor functions. Psychopharmacology 90:287–294Google Scholar
  22. O'Malley KL, Harmon S, Tang L, Han S, Todd RD (1991) Isolation and characterization of the rat dopamine D4 receptor. Soc Neurosci Abstr 17:598Google Scholar
  23. Pizzolato G, Soncrant TT, Larson DM, Rapoport SI (1987) Stimulatory effect of the D2 antagonist sulpiride on glucose utilization in dopaminergic regions of rat brain. J Neurochem 49:631–638Google Scholar
  24. Prosser ES, Pruthi R, Csernansky JG (1989) Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology 99:109–116Google Scholar
  25. Radhakishun FS, Van Ree JM (1987) The hypomotility elicited by small doses of apomorphine seems exclusively mediated by dopaminergic systems in the nucleus accumbens. Eur J Pharmacol 136:41–47Google Scholar
  26. Scatton B (1977) Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic turnover. Eur J Pharmacol 46:363–369Google Scholar
  27. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313Google Scholar
  28. Severson JA, Robinson HE, Simpson GM (1984) Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug. Psychopharmacology 84:115–119Google Scholar
  29. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–150Google Scholar
  30. Strong R (1988) Regionally selective manifestations of neostriatal aging. Ann NY Acad Sci 515:161–177Google Scholar
  31. Sutherland RJ (1982) The dorsal diencephalic conduction system: a review of the anatomy and functions of the habenular complex. Neurosci Behav Rev 6:1–13Google Scholar
  32. Van Tol HHM, Bunzow JR, Guan H-C Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozaphine. Nature 350:610–614Google Scholar
  33. Walters JR, Roth RH (1976) Dopaminergic neurons; an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 296:5–14Google Scholar
  34. Wang RY, Aghajanian GK (1977) Physiological evidence for habenula as major link between forebrain and midbrain raphe. Science 197:89–91Google Scholar
  35. Watanabe H (1984) Activation of dopamine synthesis in mesolimbic dopamine neurons by immobilization stress in the rat. Neuropharmacology 23:1335–1338Google Scholar
  36. Welling PG (1986) Pharmacokinetics. Processes and mathematics. American Chemical Society, Washington, DCGoogle Scholar
  37. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1057Google Scholar
  38. Wilmot CA, Szczepanik AM (1989) Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487:288–298Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • John G. Csernansky
    • 1
  • Catherine T. Wrona
    • 1
  • Mark E. Bardgett
    • 1
  • Terrance S. Early
    • 1
  • John W. Newcomer
    • 1
  1. 1.Department of PsychiatryWashington University School of MedicineSt LouisUSA

Personalised recommendations